Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality

Biotechnology and Bioengineering

Volumn 114, Issue 7, 2017, Pages 1448-1458

  Brühlmann, David ^a,b   Sokolov, Michael ^c   Butté, Alessandro ^c   Sauer, Markus ^b   Hemberger, Jürgen ^d   Souquet, Jonathan ^a   Broly, Hervé ^a   Jordan, Martin ^a  

^a Biotech Process Sciences   (Switzerland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c ETH ZURICH   (Switzerland)

^d TECHNISCHE HOCHSCHULE MITTELHESSEN   (Germany)

Author keywords

antibody glycosylation; CHO cell culture; DoE; high throughput; multivariate analysis; sequential process development

Indexed keywords

ANIMAL CELL CULTURE; ANTIBODIES; BATCH CELL CULTURE; CELL CULTURE; DECISION TREES; DESIGN; DESIGN OF EXPERIMENTS; GLYCOSYLATION; MAMMALS; MONOCLONAL ANTIBODIES; MULTIVARIANT ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PRODUCT DESIGN; RECOMBINANT PROTEINS; SPECIFICATIONS; THROUGHPUT;

CHO CELL CULTURES; CONCENTRATION RANGES; HIGH THROUGHPUT; MAMMALIAN CELL CULTURE; MONOCLONAL ANTIBODIES (MAB); MULTI VARIATE ANALYSIS; SCREENING EXPERIMENTS; SEQUENTIAL PROCESS;

QUALITY CONTROL;

BIOSIMILAR AGENT; GLYCAN; IMMUNOGLOBULIN G1 ANTIBODY; MANNOSE; MONOCLONAL ANTIBODY; CULTURE MEDIUM; RECOMBINANT PROTEIN;

ARTICLE; CELL CULTURE TECHNIQUE; CHO CELL LINE; CLONAL CELL LINE; CULTURE MEDIUM; DECISION TREE; EXPERIMENTAL DESIGN; FED BATCH CULTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MAMMAL CELL; MULTIVARIATE ANALYSIS; PARALLEL DESIGN; PRINCIPAL COMPONENT ANALYSIS; PROCESS DESIGN; PROCESS DEVELOPMENT; PROTEIN GLYCOSYLATION; QUALITY CONTROL; SIALYLATION; ANIMAL; BATCH CELL CULTURE; BIOSYNTHESIS; CHEMISTRY; CRICETULUS; METABOLISM; PROCEDURES; PROTEIN ENGINEERING; STANDARDS; TISSUE MICROARRAY;

ANIMALS; ANTIBODIES, MONOCLONAL; BATCH CELL CULTURE TECHNIQUES; BIOSIMILAR PHARMACEUTICALS; CHO CELLS; CRICETULUS; CULTURE MEDIA; HIGH-THROUGHPUT SCREENING ASSAYS; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN ENGINEERING; QUALITY CONTROL; RECOMBINANT PROTEINS; TISSUE ARRAY ANALYSIS;

EID: 85015175359     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.26269     Document Type: Article

References (43)

1. Abu-Absi SF, Yang L, Thompson P, Jiang C, Kandula S, Schilling B, Shukla AA. 2010. Defining process design space for monoclonal antibody cell culture. Biotechnol Bioeng 106:894–905.
2. Aghamohseni H. 2015. Effect of culture conditions on the glycosylation patterns of mAb; university of Waterloo. 2016:1–37. http://hdl.handle.net/10012/9294.
3. Aitken M. 2016. Delivering on the potential of biosimilar medicines: The role of functioning competitive markets introduction. IMS Heal. p 1–37.
4. Amanullah A, Otero JM, Mikola M, Hsu A, Zhang J, Aunins J, Schreyer HB, Hope JA, Russo AP. 2010. Novel micro-bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed-batch CHO cultures. Biotechnol Bioeng 106:57–67. http://www.ncbi.nlm.nih.gov/pubmed/20073088.
5. Bhambure R, Kumar K, Rathore AS. 2011. High-throughput process development for biopharmaceutical drug substances. Trends Biotechnol 29:127–135. https://doi.org/10.1016/j.tibtech.2010.12.001
6. Biosimilars approved in Europe. 2016. GaBI Online. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe.
7. Brühlmann D, Jordan M, Hemberger J, Sauer M, Stettler M, Broly H. 2015. Tailoring recombinant protein quality by rational media design. Biotechnol Prog 31:615–629. http://doi.wiley.com/10.1002/btpr.2089.
8. Butler M, Meneses-Acosta A. 2012. Recent advances in technology supporting biopharmaceutical production from mammalian cells. Appl Microbiol Biotechnol 96:885–894. http://www.ncbi.nlm.nih.gov/pubmed/23053101.
9. Chugh PK, Roy V. 2014. Biosimilars: Current scientific and regulatory considerations. Curr Clin Pharmacol 9:53–63. http://www.scopus.com/inward/record.url?eid=2-s2.0-84894066863&partnerID=tZOtx3y1.
10. del Val IJ, Polizzi KM, Kontoravdi C. 2016. A theoretical estimate for nucleotide sugar demand towards chinese hamster ovary cellular glycosylation. Sci Rep 6:28547. http://www.nature.com/articles/srep28547.
11. Dengl S, Wehmer M, Hesse F, Lipsmeier F, Popp O, Lang K. 2013. Aggregation and chemical modification of monoclonal antibodies under upstream processing conditions. Pharm Res 30:1380–1399. http://link.springer.com/10.1007/s11095-013-0977-8.
12. De Maesschalck R, Jouan-Rimbaud D, Massart DL. 2000. The mahalanobis distance. Chemom Intell Lab Syst 50:1–18. http://linkinghub.elsevier.com/retrieve/pii/S0169743999000477.
13. Ecker DM, Jones SD, Levine HL. 2015. The therapeutic monoclonal antibody market. MAbs 7:9–14. http://www.tandfonline.com/doi/full/10.4161/19420862.2015.989042.
14. Fan Y, Jimenez Del Val I, Müller C, Lund AM, Sen JW, Rasmussen SK, Kontoravdi C, Baycin-Hizal D, Betenbaugh MJ, Weilguny D, Andersen MR. 2015. A multi-pronged investigation into the effect of glucose starvation and culture duration on fed-batch CHO cell culture. Biotechnol Bioeng 112:2172–2184.
15. Grainger RK, James DC. 2013. CHO cell line specific prediction and control of recombinant monoclonal antibody N-glycosylation. Biotechnol Bioeng 110:2970–2983. http://www.ncbi.nlm.nih.gov/pubmed/23737295.
16. Hossler P. 2012. Protein glycosylation control in Mammalian cell culture: Past precedents and contemporary prospects. Adv Biochem Eng Biotechnol 127:187–219. http://link.springer.com/chapter/10.1007/10_2011_113%5Cn, http://www.ncbi.nlm.nih.gov/pubmed/22015728.
17. Hou Y, Jiang C, Shukla AA, Cramer SM. 2011. Improved process analytical technology for protein a chromatography using predictive principal component analysis tools. Biotechnol Bioeng 108:59–68.
18. Ivarsson M, Villiger TK, Morbidelli M, Soos M. 2014. Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylation. J Biotechnol 188C:88–96. http://www.ncbi.nlm.nih.gov/pubmed/25173615
19. Jimenez del Val I, Fan Y, Weilguny D. 2016. Dynamics of immature mAb glycoform secretion during CHO cell culture: An integrated modelling framework. Biotechnol J 11(5):610–623.
20. Jolliffe IT. 2002. Springer series in statistics. Principal component analysis. New York: Springer-Verlag. 488 pages. http://link.springer.com/10.1007/b98835.
21. Jordan M, Stettler M. 2014. Tools for high-throughput process and medium optimization. Methods Mol Biol 1104:77–88. http://www.ncbi.nlm.nih.gov/pubmed/24297410.
22. Jordan M, Voisard D, Berthoud A, Tercier L, Kleuser B, Baer G, Broly H. 2013. Cell culture medium improvement by rigorous shuffling of components using media blending. Cytotechnology 65:31–40. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3536872&tool=pmcentrez&rendertype=abstract.
23. Kishishita S, Nishikawa T, Shinoda Y, Nagashima H, Okamoto H, Takuma S, Aoyagi H. 2015. Effect of temperature shift on levels of acidic charge variants in IgG monoclonal antibodies in Chinese hamster ovary cell culture. J Biosci Bioeng 119:700–705. https://doi.org/10.1016/j.jbiosc.2014.10.028.
24. Kremkow B, Lee K. 2013. Next-generation sequencing technologies and their potential impact on CHO cell-based biomanufacturing. Pharm Bioprocess 1:455–465. http://www.future-science.com/doi/abs/10.4155/pbp.13.52.
25. Kumar R, Singh J. 2014. Biosimilar drugs: Current status. Int J Appl Basic Med Res 4:63. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4137643&tool=pmcentrez&rendertype=abstract.
26. Legmann R, Schreyer HB, Combs RG, McCormick EL, Russo AP, Rodgers ST. 2009. A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells. Biotechnol Bioeng 104:1107–1120. http://www.ncbi.nlm.nih.gov/pubmed/19623562
27. Li EC, Abbas R, Jacobs IA, Yin D. 2015. Considerations in the early development of biosimilar products. Drug Discov Today 20:1–9. http://www.sciencedirect.com/science/article/pii/S1359644614004887.
28. McGill R, Tukey JW, Larsen WA. 1978. Variations of Box Plots. Am Stat Vol 32:12–16.
29. Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691–697. http://press.endocrine.org/doi/abs/10.1210/jcem-51-4-691.
30. Morrison C. 2016. Fresh from the biotech pipeline—2015. Nat Biotechnol 34:129–132. http://www.nature.com/doifinder/10.1038/nbt.2811
31. Rouiller Y, Bielser J-M, Brühlmann D, Jordan M, Broly H, Stettler M. 2016. Screening and assessment of performance and molecule quality attributes of industrial cell lines across different fed-batch systems. Biotechnol Prog 32:160–170. http://doi.wiley.com/10.1002/btpr.2186
32. Rouiller Y, Périlleux A, Collet N, Jordan M, Stettler M, Broly H. 2013. A high-throughput media design approach for high performance mammalian fed-batch cultures. MAbs 5:501–511. http://www.ncbi.nlm.nih.gov/pubmed/23563583
33. Rouiller Y, Périlleux A, Marsaut M, Stettler M, Vesin M-N, Broly H. 2012. Effect of hydrocortisone on the production and glycosylation of an Fc-fusion protein in CHO cell cultures. Biotechnol Prog 28:803–813. http://www.ncbi.nlm.nih.gov/pubmed/22535835.
34. Rouiller Y, Périlleux A, Vesin M-N, Stettler M, Jordan M, Broly H. 2014. Modulation of mAb quality attributes using microliter scale fed-batch cultures. Biotechnol Prog 30:571–583. www.ncbi.nlm.nih.gov/pubmed/24777991.
35. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457–462. http://www.ncbi.nlm.nih.gov/pubmed/12119747.
36. Schellekens H, Ryff JC. 2002. “ Biogenerics”: The off-patent biotech products. Trends Pharmacol Sci 23:119–121.
37. Sokolov M, Ritscher J, MacKinnon N, Bielser J-M, Brühlmann D, Rothenhäusler D, Thanei G, Soos M, Stettler M, Souquet J, Broly H, Morbidelli M, Butté A. 2016. Robust factor selection in early cell culture process development for the production of a biosimilar monoclonal antibody. Biotechnol Prog 33(1):181–191. http://doi.wiley.com/10.1002/btpr.2374.
38. Sokolov M, Soos M, Neunstoecklin B, Morbidelli M, Butté A, Leardi R, Solacroup T, Stettler M, Broly H. 2015. Fingerprint detection and process prediction by multivariate analysis of fed-batch monoclonal antibody cell culture data. Biotechnol Prog 31:1633–1644.
39. Sou SN, Sellick C, Lee K, Mason A, Kyriakopoulos S, Polizzi KM, Kontoravdi C. 2015. How does mild hypothermia affect monoclonal antibody glycosylation? Biotechnol Bioeng 112:1165–1176.
40. St Amand MM, Radhakrishnan D, Robinson AS, Ogunnaike BA. 2014. Identification of manipulated variables for a glycosylation control strategy. Biotechnol Bioeng 111:1957–1970. http://onlinelibrary.wiley.com/doi/10.1002/bit.21598/full.
41. Tharmalingam T, Wu CH, Callahan S, Goudar CT. 2015. A framework for real-time glycosylation monitoring (RT-GM) in mammalian cell culture. Biotechnol Bioeng 112:1146–1154.
42. Thomassen YE, Van Sprang ENM, Van Der Pol LA, Bakker WAM. 2010. Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol Bioeng 107:96–104.
43. Tovey MG, Lallemand C. 2011. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2:113–128. http://www.ncbi.nlm.nih.gov/pubmed/22114889.